glp 1 nejm on X: "GLP-1 receptor agonists can reduce the risk of adverse cardiovascular events in pts with diabetes. Whether the GLP-1 receptor agonist semaglutide can also reduce cardiovascular risk in pts with retatrutide mechanism glp-1 gip glucagon

The Lancet .

Many patients come in asking about semaglutide because its the name theyve encountered most Ozempic has been in the news for years

These medicines work by mimicking the action of naturally occurring GLP-1, an incretin hormone released by the intestine in response to food intake

"There have also been many other side effects reported, such as nausea, vomiting, headaches, kidney failure, and you can also get brain swelling," Dr Yip said

Additional information Supplementary Information accompanies this paper on European Journal of Clinical Nutrition website Supplementary information Rights and permissions About this article Cite this article Sinha, R., Sinha, I., Calcagnotto, A

Gupta AK, Teasell EM, Economopoulos V, Mirmirani P